First Time Loading...

Prelude Therapeutics Inc
NASDAQ:PRLD

Watchlist Manager
Prelude Therapeutics Inc Logo
Prelude Therapeutics Inc
NASDAQ:PRLD
Watchlist
Price: 4.12 USD Market Closed
Updated: May 21, 2024

Intrinsic Value

PRLD's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Prelude Therapeutics, Inc. operates as a cancer drug discovery company. [ Read More ]

The intrinsic value of one PRLD stock under the Base Case scenario is 4.24 USD. Compared to the current market price of 4.12 USD, Prelude Therapeutics Inc is Undervalued by 3%.

Key Points:
PRLD Intrinsic Value
Base Case
4.24 USD
Undervaluation 3%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Prelude Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling PRLD stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Prelude Therapeutics Inc

Provide an overview of the primary business activities
of Prelude Therapeutics Inc.

What unique competitive advantages
does Prelude Therapeutics Inc hold over its rivals?

What risks and challenges
does Prelude Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Prelude Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Prelude Therapeutics Inc.

Provide P/S
for Prelude Therapeutics Inc.

Provide P/E
for Prelude Therapeutics Inc.

Provide P/OCF
for Prelude Therapeutics Inc.

Provide P/FCFE
for Prelude Therapeutics Inc.

Provide P/B
for Prelude Therapeutics Inc.

Provide EV/S
for Prelude Therapeutics Inc.

Provide EV/GP
for Prelude Therapeutics Inc.

Provide EV/EBITDA
for Prelude Therapeutics Inc.

Provide EV/EBIT
for Prelude Therapeutics Inc.

Provide EV/OCF
for Prelude Therapeutics Inc.

Provide EV/FCFF
for Prelude Therapeutics Inc.

Provide EV/IC
for Prelude Therapeutics Inc.

Show me price targets
for Prelude Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Prelude Therapeutics Inc?

How accurate were the past Revenue estimates
for Prelude Therapeutics Inc?

What are the Net Income projections
for Prelude Therapeutics Inc?

How accurate were the past Net Income estimates
for Prelude Therapeutics Inc?

What are the EPS projections
for Prelude Therapeutics Inc?

How accurate were the past EPS estimates
for Prelude Therapeutics Inc?

What are the EBIT projections
for Prelude Therapeutics Inc?

How accurate were the past EBIT estimates
for Prelude Therapeutics Inc?

Compare the revenue forecasts
for Prelude Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Prelude Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Prelude Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Prelude Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Prelude Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Prelude Therapeutics Inc with its peers.

Analyze the financial leverage
of Prelude Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Prelude Therapeutics Inc.

Provide ROE
for Prelude Therapeutics Inc.

Provide ROA
for Prelude Therapeutics Inc.

Provide ROIC
for Prelude Therapeutics Inc.

Provide ROCE
for Prelude Therapeutics Inc.

Provide Gross Margin
for Prelude Therapeutics Inc.

Provide Operating Margin
for Prelude Therapeutics Inc.

Provide Net Margin
for Prelude Therapeutics Inc.

Provide FCF Margin
for Prelude Therapeutics Inc.

Show all solvency ratios
for Prelude Therapeutics Inc.

Provide D/E Ratio
for Prelude Therapeutics Inc.

Provide D/A Ratio
for Prelude Therapeutics Inc.

Provide Interest Coverage Ratio
for Prelude Therapeutics Inc.

Provide Altman Z-Score Ratio
for Prelude Therapeutics Inc.

Provide Quick Ratio
for Prelude Therapeutics Inc.

Provide Current Ratio
for Prelude Therapeutics Inc.

Provide Cash Ratio
for Prelude Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Prelude Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Prelude Therapeutics Inc?

What is the current Free Cash Flow
of Prelude Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Prelude Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Prelude Therapeutics Inc

Current Assets 205.4m
Cash & Short-Term Investments 201.9m
Other Current Assets 3.4m
Non-Current Assets 41.7m
PP&E 37.4m
Other Non-Current Assets 4.3m
Current Liabilities 17.6m
Accounts Payable 5.3m
Accrued Liabilities 11.5m
Other Current Liabilities 800k
Non-Current Liabilities 18.7m
Other Non-Current Liabilities 18.7m
Efficiency

Earnings Waterfall
Prelude Therapeutics Inc

Revenue
0 USD
Operating Expenses
-137.5m USD
Operating Income
-137.5m USD
Other Expenses
12m USD
Net Income
-125.5m USD

Free Cash Flow Analysis
Prelude Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

PRLD Profitability Score
Profitability Due Diligence

Prelude Therapeutics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

41/100
Profitability
Score

Prelude Therapeutics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

PRLD Solvency Score
Solvency Due Diligence

Prelude Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Prelude Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PRLD Price Targets Summary
Prelude Therapeutics Inc

Wall Street analysts forecast PRLD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PRLD is 5.92 USD with a low forecast of 3.03 USD and a high forecast of 10.5 USD.

Lowest
Price Target
3.03 USD
26% Downside
Average
Price Target
5.92 USD
44% Upside
Highest
Price Target
10.5 USD
155% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Competitors Analysis
Prelude Therapeutics Inc

Ownership

PRLD Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

PRLD Price
Prelude Therapeutics Inc

1M 1M
+7%
6M 6M
+28%
1Y 1Y
-25%
3Y 3Y
-89%
5Y 5Y
-84%
10Y 10Y
-84%
Annual Price Range
4.12
52w Low
1.69
52w High
5.94
Price Metrics
Average Annual Return 5.02%
Standard Deviation of Annual Returns 132.36%
Max Drawdown -98%
Shares Statistics
Market Capitalization 226.3m USD
Shares Outstanding 54 930 000
Percentage of Shares Shorted 3.66%

PRLD Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Prelude Therapeutics Inc Logo
Prelude Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

226.3m USD

Dividend Yield

0%

Description

Prelude Therapeutics, Inc. operates as a cancer drug discovery company. The company is headquartered in Wilmington, Delaware and currently employs 116 full-time employees. The company went IPO on 2020-09-25. The firm is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers. Its drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders. The firm is developing therapies in both solid tumors and hematological malignancies, such as adenoid cystic carcinoma (ACC), homologous recombination deficient positive (HRD+), cancers, myelofibrosis (MF) and glioblastoma multiforme (GBM), amongst others. The Company’s product candidates include PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT-K4.

Contact

DELAWARE
Wilmington
200 Powder Mill Road
+13024671280.0
https://preludetx.com/

IPO

2020-09-25

Employees

116

Officers

Founder, CEO & Director
Dr. Krishna Vaddi D.V.M., Ph.D.
President & Chief Medical Officer
Dr. Edna Huang M.D.
Chief Scientific Officer
Dr. Peggy A. Scherle Ph.D.
Chief Financial Officer
Mr. Laurent Chardonnet M.B.A.
Senior VP and Head of Strategic Planning & Operations
Ms. Aimee Crombie Ph.D.
Senior Vice President of Technical Operations
Dr. Madhu Pudipeddi Ph.D.
Show More
Vice President of Investor Relations
Lindsey Trickett
Chief Legal Officer & Corporate Secretary
Mr. Bryant David Lim J.D.
Chief People Officer
Ms. Michele Porreca M.B.A.
Executive VP & Head of Chemistry
Dr. Andrew P. Combs Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one PRLD stock?

The intrinsic value of one PRLD stock under the Base Case scenario is 4.24 USD.

Is PRLD stock undervalued or overvalued?

Compared to the current market price of 4.12 USD, Prelude Therapeutics Inc is Undervalued by 3%.